BridgeBio Pharma (BBIO) stock recently moved after AstraZeneca reported that its CARDIO-TTRansform trial of Wainua in ATTR-CM did not meet its primary endpoint, a development that directly affects expectations around Attruby’s competitive position.

BridgeBio Pharma’s share price has been volatile in recent sessions, with a 1-day share price return that fell 4.75% after rallying 11.27% over 7 days and 28.58% over 30 days. The 1-year total shareholder return of 84.83% and very large 3-year total shareholder return near 7x highlight how recent news on Attruby, the infigratinib data and the preferred equity raise are feeding into a longer-term rerating.

If BridgeBio Pharma’s recent swings have your attention, this could be a good moment to widen your search using a healthcare focused AI stocks screener such as 41 healthcare AI stocks

With BridgeBio Pharma now at US$85.89 against an average analyst target near US$104 and a wide spread to some intrinsic value estimates, the key issue is where fair value really sits after the recent swing.

Most Popular Narrative: 16.4% Undervalued

BridgeBio Pharma’s most followed narrative anchors fair value at $102.71 per share, above the last close at $85.89. This puts recent volatility into sharper context.

The company's late-stage pipeline, with three Phase III readouts imminent across high unmet need rare disease indications, positions BridgeBio to leverage advancements in biotechnology for potential first-to-market and best-in-class therapies. This creates the opportunity for multiple revenue inflection points and margin improvement as the portfolio diversifies. Established commercial and patient support infrastructure, enabled by strong sales execution and white-glove access models, is expected to be redeployed for future launches, reducing incremental fixed costs per new product and supporting long-term operational leverage and net margin expansion.

Want to see what is baked into that fair value for BridgeBio Pharma? Revenue curves, margin expansion and a future earnings profile all pull hard on the model. Curious which assumptions really move the needle? The full narrative lays out the numbers in detail.

Result: Fair Value of $102.71 (UNDERVALUED)

However, the BridgeBio Pharma narrative still hinges on successful late stage trial outcomes, as well as on Attruby avoiding payer pushback that could limit future revenue and profit potential.

Another View: What Multiples Say About BridgeBio Pharma

The SWS DCF model points to very large upside for BridgeBio Pharma, with a fair value estimate of $341.71 versus the current $85.89. However, the market is pricing the stock on a rich 29x P/S ratio compared with 11.8x for US biotechs and a 23.4x fair ratio.

That gap suggests investors are already paying a premium for BridgeBio Pharma’s growth story, even as the model flags meaningful upside. The real question is whether you think the business can grow into both the premium multiple and the DCF fair value, or if one of those views will have to give.

Next Steps

With a mix of optimism and concern around BridgeBio Pharma, this is the moment to check the numbers yourself and decide what really matters. To see how the positives and negatives stack up side by side, review the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond BridgeBio Pharma?

If BridgeBio Pharma has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with a few curated stock ideas that fit different priorities.

• Target potential mispricings by checking companies that screen as high quality and undervalued through the 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that feature resilient balance sheets and yields in the 9 dividend fortresses.
• Prioritise resilience by scanning companies with lower risk profiles using the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.